Free Trial

XOMA Q4 2022 Earnings Report

XOMA logo
$30.69 -0.97 (-3.06%)
(As of 01:15 PM ET)

XOMA EPS Results

Actual EPS
-$0.64
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

XOMA Revenue Results

Actual Revenue
$1.49 million
Expected Revenue
$1.62 million
Beat/Miss
Missed by -$130.00 thousand
YoY Revenue Growth
N/A

XOMA Announcement Details

Quarter
Q4 2022
Time
N/A
Strange: Why is Amazon suddenly yielding 39.70%? (Ad)

Something big is happening with Amazon stock… While most investors collect ZERO dividends from Amazon… A small group just discovered a "backdoor" way to collect yields up to 39.70%!

Click here to see this breakthrough before everyone else →

XOMA Earnings Headlines

XOMA (NASDAQ:XOMA) Earns Buy Rating from HC Wainwright
Fed Declares War on Americans
Fed Declares War on Americans Protect your wealth in the coming months…
Strategic Acquisitions and Growth Potential Bolster Xoma’s Buy Rating
See More XOMA Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like XOMA? Sign up for Earnings360's daily newsletter to receive timely earnings updates on XOMA and other key companies, straight to your email.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

View XOMA Profile

More Earnings Resources from MarketBeat